1. Home
  2. CUE vs ULBI Comparison

CUE vs ULBI Comparison

Compare CUE & ULBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$31.81

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo Ultralife Corporation

ULBI

Ultralife Corporation

HOLD

Current Price

$5.37

Market Cap

107.6M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUE
ULBI
Founded
2014
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
107.6M
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
CUE
ULBI
Price
$31.81
$5.37
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$120.00
N/A
AVG Volume (30 Days)
137.0K
25.4K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
61.11
N/A
EPS
N/A
N/A
Revenue
$27,466,000.00
$191,159,000.00
Revenue This Year
N/A
$20.00
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
195.75
16.24
52 Week Low
$0.17
$4.90
52 Week High
$45.50
$8.72

Technical Indicators

Market Signals
Indicator
CUE
ULBI
Relative Strength Index (RSI) 53.40 39.05
Support Level $24.49 $4.95
Resistance Level $32.82 $6.14
Average True Range (ATR) 4.17 0.26
MACD -0.22 0.00
Stochastic Oscillator 31.96 31.35

Price Performance

Historical Comparison
CUE
ULBI

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company also designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

Share on Social Networks: